NAD+ reconstitution calculator

Enter your vial amount and target dose. DrawDose returns the BAC water volume, syringe units, and a vial label you can copy.

What NAD+ is and why it's different from the other compounds on DrawDose

NAD+ is not a peptide. It is nicotinamide adenine dinucleotide, an endogenous coenzyme present in every living cell. NAD+ functions in two distinct roles in cellular biochemistry. As a redox cofactor, it cycles between NAD+ and NADH forms during energy metabolism (glycolysis, the citric acid cycle, oxidative phosphorylation). As a substrate, it is consumed by enzymes including the sirtuins (SIRT1-SIRT7, involved in gene expression regulation and longevity signaling), the PARPs (involved in DNA repair), and CD38 (involved in immune cell signaling and calcium mobilization).

NAD+ is included on DrawDose because the lyophilized injectable form is widely sold in the same research peptide marketplace as the peptides covered on other pages, follows the same reconstitution math, and is dosed using the same insulin syringe workflow. The calculator's underlying math (concentration = mass / volume; syringe units = dose / concentration × 100) applies to NAD+ identically to peptides.

The biology and the clinical evidence are different. The other compounds covered on DrawDose are peptides with relatively well-characterized receptor mechanisms and reasonable consistency in published efficacy data. NAD+ supplementation has well-characterized biochemistry but a meaningfully contested clinical evidence base. The editorial register of this page reflects that — claims that proponents make versus claims that the published literature actually supports are not always the same thing.

The membrane permeability problem

Per the Frontiers in Aging 2024 retrospective tolerability pilot study and the broader NAD+ supplementation literature, extracellular NAD+ does not readily cross cell membranes intact. When NAD+ is administered intravenously or subcutaneously, the NAD+ molecule is hydrolyzed extracellularly into smaller components — NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and NAM (nicotinamide) — which are then absorbed into cells through molecule-specific transporters and reassembled into intracellular NAD+ via the salvage pathway.

This means that injected NAD+ functions, mechanistically, as a delivery vehicle for its degradation products rather than as direct intracellular NAD+ supplementation. The proponent argument is that direct NAD+ administration produces higher intracellular NAD+ elevation than precursor supplementation; the skeptic argument is that NMN or NR oral supplementation achieves the same or better intracellular NAD+ elevation more efficiently and with fewer adverse effects.

Per the Frontiers in Aging 2024 study comparing 500 mg NAD+ IV versus 500 mg NR IV across 4 consecutive days, both routes elevated NAD+ levels, but the NAD+ IV arm reported significantly more adverse events including nausea, chest pain, muscle cramping, and dizziness. The NR IV arm produced equivalent NAD+ elevation with markedly better tolerability.

The Radenkovic et al. 2020 review in Pharmaceuticals provides additional context on the precursor debate. Of 36 human trials with published results identified in the review, 18 used oral NAD+ precursor supplementation (NMN, NR, nicotinamide), 8 used oral NAD+, and the remainder used various other approaches. The published efficacy data is dominated by oral precursor trials rather than direct injectable NAD+ trials.

This editorial does not resolve the debate. The page presents the contested evidence and the dosing math; users decide based on their own evaluation of the literature.

The age-related decline thesis

NAD+ levels decline with age across multiple tissues. Per the Song et al. 2023 review in Advances in Nutrition, NAD+ concentrations have been documented to decrease with age in human skin, blood, liver, muscle, and brain. The mechanisms involve reduced biosynthesis (lower NAMPT enzyme activity), increased consumption (elevated CD38 activity in older tissues), and altered tryptophan-to-NAD+ pathway flux.

The longevity hypothesis underlying NAD+ supplementation is that restoring NAD+ levels to those characteristic of younger tissue reverses or slows age-related cellular dysfunction. The mechanism would operate via sirtuin activation (SIRT1-SIRT7 require NAD+ as substrate; depleted NAD+ limits sirtuin-mediated gene regulation), PARP function preservation (DNA repair enzymes also require NAD+), and metabolic restoration.

This hypothesis is supported by preclinical data in mouse models and by some human biomarker data showing improved metabolic parameters with NAD+ precursor supplementation. The hypothesis is not yet supported by human longevity outcome data — no controlled trial has demonstrated that NAD+ supplementation extends human healthspan or lifespan, because such trials would require decades to complete. The "NAD+ supplementation extends lifespan" claim that appears in some marketing materials is currently extrapolation from preclinical and biomarker data, not direct human evidence.

Quick answer for the most common vial sizes

The 5 mL : 500 mg ratio documented across compounding pharmacy formulation guides for NAD+ produces a 100 mg/mL concentration, where every 100 units delivers 100 mg.

The math holds at any concentration. DrawDose accepts any vial size and any BAC water volume and returns the correct syringe draw for the dose entered.

The 100 mg/mL ratio is the standard for NAD+ because it puts the typical 100 mg per-injection dose at exactly 100 units — a full 1 mL syringe, easy to draw and verify. Higher concentrations (200 mg/mL) reduce injection volume but produce more concentrated solutions that can sting more during subcutaneous administration. Doses above 200 mg per injection typically use a 3 mL syringe rather than splitting across two 1 mL syringe injections.

How to reconstitute lyophilized NAD+

The procedure follows the standard sterile-injection prep workflow with one consideration specific to NAD+: the molecule is somewhat acidic in solution (pH approximately 4-5 when reconstituted with bacteriostatic water at standard concentrations), which contributes to the "stinging" sensation users report on subcutaneous injection.

Bring the vial and BAC water to room temperature for 15 to 20 minutes before mixing. Wipe both vial tops with an alcohol swab and let them dry. Draw the BAC water into a syringe.

Insert the needle into the NAD+ vial at an angle so the water runs down the inside wall. Once the water is in, swirl the vial gently for 20 to 30 seconds. Do not shake. Properly reconstituted NAD+ is clear and pale yellow; cloudiness or unusual color indicates a sourcing concern.

Some clinical practitioners administering NAD+ subcutaneously add a small amount of buffering agent (sodium bicarbonate or saline buffer) to reduce injection-site pain. The compounded versions sold by some pharmacies arrive pre-buffered. Self-mixing buffer additions is not recommended without specific compounding pharmacy guidance.

Why concentration determines syringe units

The relationship between vial size, BAC water, and syringe draw is fixed by concentration math. A 500 mg vial with 5 mL of water gives 100 mg/mL — every 100 units delivers 100 mg, so a 100 mg dose draws as 100 units (a full 1 mL insulin syringe). The same 500 mg vial with 2.5 mL of water gives 200 mg/mL, where 100 units delivers 200 mg. To hit a 100 mg target dose at 200 mg/mL, the draw is 50 units.

Standard reconstitution practice for NAD+ keeps the draw between 25 and 250 units depending on the dose target. NAD+'s typical 100-200 mg per-injection dose at 100 mg/mL produces draws in the 100-200 unit range, which often requires either a full 1 mL syringe or splitting across two injections. DrawDose computes this automatically; the auto-selected BAC water volume on the result panel is tuned to keep the draw practical.

Documented dosing protocols

There are no FDA-approved injectable NAD+ dosing protocols. Injectable NAD+ products are not FDA-approved as drugs; they are sold as research compounds or distributed through compounding pharmacies operating under state-specific compounding regulations.

The most common published dosing reference is the Frontiers in Aging 2024 retrospective study, which evaluated 500 mg NAD+ IV daily for 4 consecutive days. This is consistent with the IV NAD+ protocols offered by commercial wellness clinics, which typically administer 500-1000 mg over 4 hours via slow IV infusion across multiple consecutive days.

The active ChromaDex Phase 1 trial of injectable NR (NCT07251608, recruiting as of April 2026) is evaluating 50 mg or 100 mg subcutaneous or intramuscular doses three times weekly. This is a different molecule (NR rather than NAD+ proper) but provides the most rigorous clinical reference for self-administered injectable NAD-system supplementation currently in trials.

Community protocol surveys aggregated from r/Peptides, r/NMN, and longevity-focused forums describe injectable NAD+ dosing as follows.

The standard subcutaneous dose is 50 to 200 mg per injection, administered 1 to 3 times weekly. The most common pattern is 100 mg three times weekly (Monday, Wednesday, Friday). Some users running aggressive longevity protocols dose 200 mg twice weekly; others run shorter cycles at 500 mg daily for 4-7 days followed by a maintenance phase.

Cycle length in community practice runs 4 to 12 weeks of active dosing followed by a 2 to 4 week off period, or continuous dosing without cycles. The clinical-practice rationale for cycling is unclear — unlike receptor-based peptides where cycling preserves receptor sensitivity, NAD+ supplementation operates via biochemistry that doesn't have an obvious downregulation mechanism.

For comparison: oral NMN supplementation protocols in the Song et al. 2023 review used doses of 250-1000 mg per day. Oral NR supplementation protocols typically use 250-1000 mg per day. The injectable NAD+ doses (100-200 mg subcutaneous) are substantially lower than oral precursor doses but achieve different pharmacokinetic profiles.

NMN, NR, and the FDA's 2022 ruling

The published clinical trial literature on NAD+ system supplementation is dominated by NMN and NR research rather than direct NAD+ research. Both NMN and NR are precursors that feed into the NAD+ salvage pathway. Both have demonstrated, in human trials, the ability to elevate blood NAD+ levels.

In November 2022, the FDA declared β-NMN (the most-studied NMN form) prohibited as a dietary supplement. The ruling related specifically to Metro International Biotech LLC's investigation of MIB-626 (a proprietary β-NMN form) as an investigational new drug. Per the FDA's interpretation of the Federal Food, Drug, and Cosmetic Act, a substance under investigation as a drug cannot simultaneously be marketed as a dietary supplement.

The 2022 ruling created a complicated regulatory landscape. NMN remains legal to research and to compound at compounding pharmacies; it is also still sold through some channels. The marketplace has shifted toward NR as the dietary-supplement-legal alternative, though NR has its own complexities (Niagen, the patented NR chloride form, is owned by ChromaDex and is the form used in the active Phase 1 injectable trial).

For users considering NAD+ system supplementation, the practical decision tree is approximately: oral NR is the most widely available legal supplement form; oral NMN is contested but still accessible through some channels; injectable NAD+ is sold through research peptide markets and some compounding pharmacies; injectable NR is currently in Phase 1 trials and not yet broadly available. Each form has different evidence bases, different regulatory statuses, and different cost profiles.

Adverse reactions and safety profile

The published safety data on NAD+ supplementation differs by route and form.

Per the Frontiers in Aging 2024 study, intravenous NAD+ at 500 mg daily for 4 days produced a high rate of adverse events: nausea, diarrhea, muscle cramping, chest pain, and dizziness were all documented at meaningful frequency. The authors of the study explicitly note that "systematic investigations addressing the safety and tolerability of NAD+ IV remain limited despite its widespread use." The IV NR arm of the same study produced substantially fewer adverse events at the same dose.

Subcutaneous NAD+ has thinner published safety data. Community protocol surveys describe the most common subjective effects as injection-site stinging or burning (related to the acidic pH of reconstituted NAD+), transient flushing, and mild gastrointestinal effects. Severe adverse events are reported at much lower frequency than with IV administration, but the published controlled trial data for subcutaneous NAD+ specifically is essentially absent.

The active ChromaDex Phase 1 trial (NCT07251608) is the most rigorous human safety evaluation currently underway for self-administered injectable NAD-system compounds. The trial uses NR rather than NAD+ proper, and at lower doses (50-100 mg) than community NAD+ protocols. Results will be available in 2026 or 2027.

Theoretical safety concerns documented across the broader NAD+ literature include CD38 paradox (high extracellular NAD+ may drive CD38-mediated immune activation), potential adverse effects in users with active infection or inflammation (NAD+ has documented immune-modulating effects), and unknown long-term effects of chronic supplementation in healthy users. Pregnancy, active malignancy, and known immune disorders are listed as contraindications across clinical-practice references for injectable NAD+ administration.

Long-term human safety data does not exist for injectable NAD+. The published trial durations extend to weeks or months, not years.

WADA prohibited status

NAD+ is not currently listed on the World Anti-Doping Agency Prohibited List as of April 2026. The compound's mechanism (cofactor for cellular metabolism) does not fall under any current WADA prohibited category. NMN and NR are similarly not listed. This may change as the prohibited list updates annually; verify the current list before assuming status.

Common reconstitution errors

Compounded peptide forums and pharmacy QA literature document a recurring set of errors specific to NAD+.

Confusing NAD+ with NADH, NMN, or NR. The four molecules are related but distinct: NAD+ is the oxidized form of nicotinamide adenine dinucleotide; NADH is the reduced form; NMN is a precursor; NR is a precursor of NMN. Vials labeled "NAD" without specifying the form may contain any of these. Verify the molecular weight on the COA: NAD+ is 663.43 g/mol, NADH is 665.4 g/mol, NMN is 334.22 g/mol, NR is 255.25 g/mol.

Drawing too small a syringe for high-dose injections. A 200 mg dose at 100 mg/mL is 200 units — beyond 1 mL insulin syringe capacity. Either use a 3 mL syringe, split across two injections, or reconstitute to 200 mg/mL to halve the draw volume.

Injecting too quickly. NAD+ subcutaneous administration is reported across community surveys as producing more discomfort with rapid push than with slow administration over 30-60 seconds. The acidic pH of the solution contributes to the burning sensation; slower infusion gives tissue better time to buffer.

Trusting IV protocol doses for subcutaneous administration. The 500-1000 mg IV doses used in commercial wellness clinics distribute across the entire vascular volume; 500 mg subcutaneously deposits the same mass into a much smaller tissue volume and produces correspondingly more local adverse effects.

Reusing reconstituted vials beyond 2 to 4 weeks. Per peptide stability literature applied to NAD+, reconstituted NAD+ remains stable for approximately 2 to 4 weeks at 2 to 8°C with bacteriostatic water containing benzyl alcohol preservative. The molecule is somewhat less stable than peptide compounds; refrigerator storage is essential.

Storage and shelf life

Per stability literature, lyophilized NAD+ stores for 24 months or longer at -20°C and 12 months or longer at 2 to 8°C. Reconstituted NAD+ stays stable for 2 to 4 weeks at 2 to 8°C (36 to 46°F) when reconstituted with bacteriostatic water. Sterile water without preservative produces a 24-hour shelf life from first puncture.

NAD+ is more sensitive to heat exposure than many peptides; vendors that ship without cold-pack insulation in summer months are flagged in community survey data as producing reduced-potency product.

What to verify on a Certificate of Analysis

The COA reports the actual content of a specific lot. Net mass is the measured milligrams of NAD+ in the vial, separate from any excipients (mannitol, sodium chloride) included for stability. Purity by HPLC reflects the percentage of UV-absorbing material that is the target molecule; 95% is the research-grade minimum, and 98% is the standard most reputable vendors publish.

Form verification (NAD+ vs NADH vs NMN vs NR) is more important for NAD-system compounds than for peptides because the four related molecules are sold under similar names but have very different molecular weights and biological functions. Mass spec confirmation against the expected molecular weight (663.43 Da for NAD+ proper) is the QC check.

Acidity verification. Properly synthesized NAD+ has a specific pKa profile; significantly elevated acidity in reconstituted product indicates degradation or contamination.

Documented combinations

NAD+ is rarely combined with peptides in community protocols because the dosing magnitudes and use cases differ substantially. Some longevity-focused protocols include NAD+ alongside peptides like sermorelin or ipamorelin, with the rationale that sirtuin activation (via NAD+) and growth hormone elevation (via the GH-stack peptides) both contribute to age-related cellular function — but the combination is theoretical convention rather than evidence-based.

NAD+ is more commonly combined with oral NAD+ precursors (NMN or NR) rather than peptides. The rationale: oral precursors maintain background NAD+ status while injectable NAD+ produces acute elevations. The combined approach has no controlled trial data evaluating it specifically.

Some longevity clinics combine IV NAD+ with other compounds like glutathione, ALA (alpha-lipoic acid), or methylcobalamin. These combinations are clinical-practice rather than evidence-based; no controlled trial has evaluated co-administered NAD+ + glutathione or similar combinations.

FAQ

Does injected NAD+ actually increase intracellular NAD+ levels?

The published literature is mixed. Per the Frontiers in Aging 2024 study and the broader NAD+ supplementation literature, extracellular NAD+ does not readily cross cell membranes intact — it is hydrolyzed extracellularly to NMN, NR, and NAM, which then cross membranes and are reassembled into intracellular NAD+. This means injected NAD+ functions mechanistically as a delivery vehicle for its degradation products. Whether this is more or less efficient than direct NMN or NR supplementation is genuinely contested.

Is NMN legal to buy in 2026?

The regulatory status is contested. In November 2022, FDA declared β-NMN prohibited as a dietary supplement because Metro International Biotech LLC was investigating it as an investigational new drug (MIB-626). NMN remains legal to research and to compound at compounding pharmacies; some retailers continue to sell it through various channels. NR (nicotinamide riboside, sold as Niagen by ChromaDex) is currently the legally clearest dietary supplement form of NAD+ precursor. Verify current regulatory status before purchasing.

Why does subcutaneous NAD+ injection sting?

NAD+ in solution is somewhat acidic (pH approximately 4-5 when reconstituted with bacteriostatic water at standard concentrations). Subcutaneous tissue has a higher physiological pH, and the acidic injection produces local tissue irritation that registers as burning or stinging. Some compounding pharmacies pre-buffer NAD+ injectable products to reduce this; self-buffering at home is not recommended without specific pharmacy guidance.

What's the difference between NAD+ IV therapy at clinics and self-administered subcutaneous NAD+?

Commercial NAD+ IV therapy typically involves slow infusion of 500-1000 mg over 4 hours, repeated daily for multiple consecutive days. Self-administered subcutaneous NAD+ typically involves 50-200 mg per injection, 1-3 times weekly. The pharmacokinetic profiles differ substantially. IV NAD+ produces acute high plasma levels and is associated with the higher adverse event rate documented in the Frontiers in Aging 2024 study; subcutaneous NAD+ produces lower-magnitude, longer-duration elevation.

Is injectable NAD+ banned by WADA?

No. As of April 2026, NAD+ is not on the World Anti-Doping Agency Prohibited List. NMN and NR are similarly not listed. The mechanism (cofactor for cellular metabolism) does not fall under any current WADA prohibited category. Verify the current list annually.

Should I use injectable NAD+, oral NMN, or oral NR?

The published efficacy data is strongest for oral NMN and oral NR, which have been studied in multiple controlled human trials for biomarker outcomes. Injectable NAD+ has thinner controlled trial data but may produce different pharmacokinetic profiles. The practical considerations: oral NR is the most legally clear form (Niagen has FDA GRAS notification); oral NMN is contested under the 2022 FDA ruling; injectable NAD+ is available through research peptide markets and some compounding pharmacies but has documented adverse event concerns at IV doses. Each form has tradeoffs that depend on individual goals and risk tolerance.

How long does it take for NAD+ supplementation to produce measurable effects?

Per the published clinical trial data on oral NMN and NR supplementation, blood NAD+ elevation is measurable within hours to days of starting supplementation. Subjective effects (energy, sleep, recovery) are reported by users in community surveys typically within 2 to 4 weeks of consistent dosing. Biomarker effects on aging-related parameters (mitochondrial function, vascular health) are documented in trials extending 8 weeks to 12 months. Longevity effects in humans are not yet documented because such outcomes would require decades-long trials.

What should I do if I have nausea or chest pain after NAD+ injection?

Per the documented adverse events in the Frontiers in Aging 2024 study, nausea, chest pain, muscle cramping, and dizziness are all documented adverse reactions to NAD+ administration, particularly at higher doses or with rapid IV administration. Mild adverse events typically resolve within an hour. Severe adverse events (sustained chest pain, difficulty breathing, severe dizziness) require immediate medical attention. Reducing the dose, slowing the injection, or switching to a precursor (NMN or NR) reduces adverse event frequency in published comparisons.